Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
72
Participants
Timeline
Start Date
March 3, 2017
Primary Completion Date
October 11, 2017
Study Completion Date
October 11, 2017
Conditions
Healthy Participants
Interventions
DRUG
E6742
gelatin capsules
DRUG
Placebo
gelatin capsules
Trial Locations (1)
91206
Parexel International, Glendale
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT03082235 - Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter